, Volume 21, Issue 1, pp 37–46 | Cite as

Notch signaling controls sprouting angiogenesis of endometriotic lesions

  • Christina Körbel
  • Miriam D. Gerstner
  • Michael D. Menger
  • Matthias W. LaschkeEmail author
Original Paper


Angiogenesis is essential for the engraftment and growth of endometriotic lesions. In this study, we analyzed whether this process is regulated by Notch signaling. Endometriotic lesions were induced by endometrial tissue transplantation into dorsal skinfold chambers of C57BL/6 mice, which were treated with the γ-secretase inhibitor DAPT or vehicle. Vascularization, morphology, and proliferation of the newly developing lesions were analyzed using intravital fluorescence microscopy, histology, and immunohistochemistry over 14 days. Inhibition of Notch signaling by DAPT significantly increased the number of angiogenic sprouts within the endometrial grafts during the first days after transplantation when compared to vehicle-treated controls. This was associated with an accelerated vascularization, as indicated by a higher functional microvessel density of DAPT-treated lesions on day 6. However, inhibition of Notch signaling did not affect the morphology and proliferating activity of the lesions, as previously described for tumors. Both DAPT- and vehicle-treated lesions finally consisted of cyst-like dilated glands, which were surrounded by a well-vascularized stroma and contained comparable numbers of proliferating cell nuclear antigen-positive cells. These findings demonstrate that sprouting angiogenesis in endometriotic lesions is controlled by Notch signaling. However, inhibition of Notch signaling does not have beneficial therapeutic effects on lesion development.


Endometriosis Angiogenesis Notch Tip cells Stalk cells γ-Secretase inhibitor 



We are grateful for the excellent technical assistance of Janine Becker, Ruth M. Nickels, Julia Parakenings, and Sandra Schuler (Institute for Clinical and Experimental Surgery, Saarland University, Germany).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. This article does not contain any studies with human participants performed by any of the authors.


  1. 1.
    Galle PC (1989) Clinical presentation and diagnosis of endometriosis. Obstet Gynecol Clin North Am 16:29–42PubMedGoogle Scholar
  2. 2.
    Viganò P, Parazzini F, Somigliana E, Vercellini P (2004) Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol 18:177–200CrossRefPubMedGoogle Scholar
  3. 3.
    Sampson JA (1927) Peritoneal endometriosis due to menstrual dissemination of endometrial tissues into the peritoneal cavity. Am J Obstet Gynecol 14:422–469CrossRefGoogle Scholar
  4. 4.
    Groothuis PG, Nap AW, Winterhager E, Grümmer R (2005) Vascular development in endometriosis. Angiogenesis 8:147–156CrossRefPubMedGoogle Scholar
  5. 5.
    Laschke MW, Menger MD (2007) In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 13:331–342CrossRefPubMedGoogle Scholar
  6. 6.
    Laschke MW, Schwender C, Scheuer C, Vollmar B, Menger MD (2008) Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo. Hum Reprod 23:2308–2318CrossRefPubMedGoogle Scholar
  7. 7.
    Taylor RN, Yu J, Torres PB, Schickedanz AC, Park JK, Mueller MD, Sidell N (2009) Mechanistic and therapeutic implications of angiogenesis in endometriosis. Reprod Sci 16:140–146CrossRefPubMedGoogle Scholar
  8. 8.
    McLaren J (2000) Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 6:45–55CrossRefPubMedGoogle Scholar
  9. 9.
    Taylor RN, Lebovic DI, Mueller MD (2002) Angiogenic factors in endometriosis. Ann N Y Acad Sci 955:89–100CrossRefPubMedGoogle Scholar
  10. 10.
    Hellström M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalén M, Gerhardt H, Betsholtz C (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445:776–780CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang P, Yan X, Chen Y, Yang Z, Han H (2014) Notch signaling in blood vessels: from morphogenesis to homeostasis. Sci China Life Sci 57:774–780CrossRefPubMedGoogle Scholar
  12. 12.
    Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284:770–776CrossRefPubMedGoogle Scholar
  13. 13.
    Sainson RC, Harris AL (2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med 13:389–395CrossRefPubMedGoogle Scholar
  14. 14.
    Purow B (2012) Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol 727:305–319CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, de Sauvage F, Plowman G, Yan M (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444:1083–1087CrossRefPubMedGoogle Scholar
  16. 16.
    Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444:1032–1037CrossRefPubMedGoogle Scholar
  17. 17.
    Nenicu A, Körbel C, Gu Y, Menger MD, Laschke MW (2014) Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions. Hum Reprod 29:1011–1024CrossRefPubMedGoogle Scholar
  18. 18.
    Laschke MW, Vorsterman van Oijen AE, Scheuer C, Menger MD (2011) In vitro and in vivo evaluation of the anti-angiogenic actions of 4-hydroxybenzyl alcohol. Br J Pharmacol 163:835–844CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Laschke MW, Menger MD (2016) The dorsal skinfold chamber: a versatile tool for preclinical research in tissue engineering and regenerative medicine. Eur Cell Mater 32:202–215CrossRefPubMedGoogle Scholar
  20. 20.
    Feng D, Menger MD, Wang H, Laschke MW (2014) Luminal epithelium in endometrial fragments affects their vascularization, growth and morphological development into endometriosis-like lesions in mice. Dis Model Mech 7:225–232CrossRefPubMedGoogle Scholar
  21. 21.
    Sjölund J, Johansson M, Manna S, Norin C, Pietras A, Beckman S, Nilsson E, Ljungberg B, Axelson H (2008) Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest 118:217–228CrossRefPubMedGoogle Scholar
  22. 22.
    Novella-Maestre E, Carda C, Noguera I, Ruiz-Saurí A, García-Velasco JA, Simón C, Pellicer A (2009) Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod 24:1025–1035CrossRefPubMedGoogle Scholar
  23. 23.
    Feng D, Welker S, Körbel C, Rudzitis-Auth J, Menger MD, Montenarh M, Laschke MW (2012) Protein kinase CK2 is a regulator of angiogenesis in endometriotic lesions. Angiogenesis 15:243–252CrossRefPubMedGoogle Scholar
  24. 24.
    Feng D, Menger MD, Laschke MW (2013) Vascular disrupting effects of combretastatin A4 phosphate on murine endometriotic lesions. Fertil Steril 100:1459–1467CrossRefPubMedGoogle Scholar
  25. 25.
    Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845CrossRefPubMedGoogle Scholar
  26. 26.
    Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D (2001) Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 69:135–144CrossRefPubMedGoogle Scholar
  27. 27.
    Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161:1163–1177CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, Wiegand SJ (2007) Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci USA 104:3219–3224CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Tung JJ, Tattersall IW, Kitajewski J (2012) Tips, stalks, tubes: notch-mediated cell fate determination and mechanisms of tubulogenesis during angiogenesis. Cold Spring Harb Perspect Med 2:a006601CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R, Djokovic D, Borges C, Ley EJ, Duarte A, Gill PS (2007) Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 109:4753–4760CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Thurston G, Noguera-Troise I, Yancopoulos GD (2007) The delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 7:327–331CrossRefPubMedGoogle Scholar
  32. 32.
    Becker CM, Beaudry P, Funakoshi T, Benny O, Zaslavsky A, Zurakowski D, Folkman J, D’Amato RJ, Ryeom S (2011) Circulating endothelial progenitor cells are up-regulated in a mouse model of endometriosis. Am J Pathol 178:1782–1791CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Laschke MW, Giebels C, Menger MD (2011) Vasculogenesis: a new piece of the endometriosis puzzle. Hum Reprod Update 17:628–636CrossRefPubMedGoogle Scholar
  34. 34.
    Laschke MW, Giebels C, Nickels RM, Scheuer C, Menger MD (2011) Endothelial progenitor cells contribute to the vascularization of endometriotic lesions. Am J Pathol 178:442–450CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Rudzitis-Auth J, Nenicu A, Nickels RM, Menger MD, Laschke MW (2016) Estrogen stimulates homing of endothelial progenitor cells to endometriotic lesions. Am J Pathol 186:2129–2142CrossRefPubMedGoogle Scholar
  36. 36.
    Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD (2006) Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 21:262–268CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  • Christina Körbel
    • 1
  • Miriam D. Gerstner
    • 1
  • Michael D. Menger
    • 1
  • Matthias W. Laschke
    • 1
    Email author
  1. 1.Institute for Clinical and Experimental SurgerySaarland UniversityHomburg/SaarGermany

Personalised recommendations